EDITOR’S LETTER
Charles B. Nemeroff, MD, PhD
Economics of Cancer Drug Development
By Michael Dickson, PhD, and Gene Reeder, PhD
Economic Impacts of Anxiety Disorders
By Ernst R. Berndt, PhD and Tamar Sisitsky, MA
Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders
By Charles B. Nemeroff, MD, PhD
Duloxetine in Military Posttraumatic Stress Disorder
By Gerardo Villarreal, José M. Cañive, Lawrence A. Calais, Gregory Toney, Ashley K. Smith
Duloxetine for the Treatment of Major Depressive Disorder
By Charles B. Nemeroff, MD, PhD, Alan F. Schatzberg, MD, David J. Goldstein, MD, PhD, Michael J. Detke, MD, PhD, Craig Mallinckrodt, PhD, Yili Lu, PhD, and Pierre V. Tran, MD
Drug–Drug Interactions Associated with Second-Generation Antipsychotics: Considerations for Clinicians and Patients
By Robert R. Conley, MD and Deanna L. Kelly, PharmD, BCPP
COMPLICATED CASE HISTORIES
Drug Induced Mania in a Boy with High Functioning Autism
By Mustafa Deniz Tutkunkardas, Nahit Motavalli Mukaddes
Drug Development for Anxiety Disorders: New Roles for Atypical Antipsychotics
By William H. Carson, MD, Hisashi Kitagawa, PhD, and Charles B. Nemeroff, MD, PhD
¡Bienvenidos a
Psiquiatría y Salud Integral!
Dr. Juan E. Mezzich y Dr. Miguel R. Jorge
Does Isotretinoin Cause Depression and Suicide?
By J. Douglas Bremner, MD
Divalproex in the Treatment of Migraine
By Frederick G. Freitag, DO
Divalproex in the Treatment of Bipolar Disorder
By Paul E. Keck, Jr, MD, and Susan L. McElroy, MD
Divalproex and Epilepsy
By L. James Willmore, MD
Diferencias de género en el trastorno depresivo mayor y el trastorno bipolar
Dra. Ellen Leibenluft
Diagnosis and Treatment of Depression in the Cancer Patient
Tracy L. Skaer, PharmD, Linda M. Robison, MSPH, David A. Sclar, PhD
Diagnosis and Staging of Gynecological Malignancies
By Brigitte E. Miller, MD
Development of STI571 and Its Use in Chronic Myelogenous Leukemia and Other Malignancies
By Michael J. Mauro, MD, Michael E. O’Dwyer, MD, and Brian J. Druker, MD
Development of Antagonists of the Platelet-Derived Growth Factor Receptor Family
By Neill A. Giese, PhD, Nathalie A. Lokker, PhD, Jin-Chen Yu, PhD, Kenji Matsuno, PhD, Michio Ichimura, PhD, Shoji Oda, PhD, Robert Scarborough, PhD, and Anjali Pandey, PhD
EVIDENCE-BASED MEDICINE
Developing and Testing Adaptive Treatment Strategies Using Substance-Induced Psychosis as an Example
By Ree Dawson, Alan I. Green, Robert E. Drake, Thomas H. McGlashan, Bella Schanzer, Philip W. Lavori
DRUG INTERACTIONS
Desvenlafaxine and Venlafaxine Exert Minimal In Vitro Inhibition of Human Cytochrome P450 and P-Glycoprotein Activities
By Aram Oganesian, Adam D. Shilling, Ruth Young-Sciame, Judy Tran, Adiba Watanyar, Farooq Azam, John Kao, Louis Leung
Depression Treatment: A Lifelong Commitment?
By Martin B. Keller, MD, and Ernst R. Berndt, PhD
Depression in the Elderly
By William M. McDonald, MD, Carl Salzman, MD, and Alan F. Schatzberg, MD